Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
Feijóo-Bandín S, Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Feijóo-Bandín S, et al. Among authors: otero santiago m. Int J Mol Sci. 2022 May 18;23(10):5634. doi: 10.3390/ijms23105634. Int J Mol Sci. 2022. PMID: 35628443 Free PMC article. Review.
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, García-Caballero T, Rodríguez-Segade S, Rodríguez J, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Aragón-Herrera A, et al. Among authors: otero santiago m. Biochem Pharmacol. 2019 Dec;170:113677. doi: 10.1016/j.bcp.2019.113677. Epub 2019 Oct 21. Biochem Pharmacol. 2019. PMID: 31647926
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Campos-Toimil M, García-Caballero T, Barral L, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González-Juanatey JR, Feijóo-Bandín S, Lago F. Aragón-Herrera A, et al. Among authors: otero santiago m. Front Pharmacol. 2022 Feb 2;13:827033. doi: 10.3389/fphar.2022.827033. eCollection 2022. Front Pharmacol. 2022. PMID: 35185578 Free PMC article.
Knowledge, Perceptions, and Perspectives of Medical Students Regarding the Use of Antibiotics and Antibiotic Resistance: A Qualitative Research in Galicia, Spain.
Vázquez-Lago JM, Montes-Villalba RA, Vázquez-Cancela O, Otero-Santiago M, López-Durán A, Figueiras A. Vázquez-Lago JM, et al. Among authors: otero santiago m. Antibiotics (Basel). 2023 Mar 11;12(3):558. doi: 10.3390/antibiotics12030558. Antibiotics (Basel). 2023. PMID: 36978424 Free PMC article.
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.
Aragón-Herrera A, Moraña-Fernández S, Otero-Santiago M, Anido-Varela L, Campos-Toimil M, García-Seara J, Román A, Seijas J, García-Caballero L, Rodríguez J, Tarazón E, Roselló-Lletí E, Portolés M, Lage R, Gualillo O, González-Juanatey JR, Feijóo-Bandín S, Lago F. Aragón-Herrera A, et al. Among authors: otero santiago m. Biomed Pharmacother. 2023 May;161:114535. doi: 10.1016/j.biopha.2023.114535. Epub 2023 Mar 15. Biomed Pharmacother. 2023. PMID: 36931025 Free article.